Compare ACADIA Pharmaceuticals Inc. (ACAD) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs AstraZeneca plc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while AstraZeneca plc trades at $158.76 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 48.9× ACADIA Pharmaceuticals Inc.'s market cap, and AstraZeneca plc pays a 2.01% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AZN | |
|---|---|---|
Market Cap | $5.07B | $248.14B |
Sector | Health | Health |
52-Week High | $29.41 | $209.48 |
52-Week Low | $20.06 | $147.06 |
Enterprise Value | $4.19B | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
